Table 1 Summary of patient population (n = 18)
From: Phase-I trial of survivin inhibition with EZN-3042 in dogs with spontaneous lymphoma
Age (years) | Median (range) | 8 (4–13) |
Weight (kg) | Median (range) | 33.8 (5.2–43.3) |
Sex | Male castrated | 9 (50%) |
Female spayed | 6 (33%) | |
Male intact | 3 (17%) | |
Breed | Mixed breed | 4 (22%) |
Golden retriever | 3 (17%) | |
Labrador retriever | 2 (11%) | |
Boxer | 2 (11%) | |
Other (1 each) | 7 (39%) | |
Immunophenotype | B | 11 (61%) |
T | 6 (33%) | |
NA | 1 (6%) | |
Lines of Previous Treatment | 0 | 9 (50%) |
1 | 3 (17%) | |
2 | 3 (17%) | |
> 2 | 3 (17%) |